Compositions and methods for diagnosis and treatment of type 2 diabetes

• US 20100197596A1
• Filed: 04/13/2010
• Published: 08/05/2010
• Est. Priority Date: 09/01/2006
• Status: Active Grant

• Current Assignee: American Type Culture Collection
• Original Assignee: American Type Culture Collection
• Inventors: Ikonomi, Pranvera, Gelber, Cohava, Liu, Liping, Xie, Zhidong, Auge, Catherine R., Simms, John R.
• Granted Patent: US 7,951,382 B2
• Time in Patent Office: Days
• US Class Current: 514/20.1
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Claims

1. A method of treating type 2 Diabetes or a pre-diabetic condition in a subject, comprising administering to the subject a pharmaceutical composition comprising as an active ingredient an isolated peptide of SEQ ID No.:

1 and a pharmaceutically acceptable carrier or diluent.

2. The method of claim 1, wherein the SEQ ID NO.:

1 is part of a fusion protein.

3. The method of claim 2, wherein the SEQ ID NO.:

1 is fused with a therapeutic protein or a targeting moiety.

4. The method of claim 1, wherein the pharmaceutical composition is co-administered with an antisense or ribozyme molecule against a kinase.

5. The method of claim 1, wherein the pharmaceutical composition is co-administered with a second therapeutic agent.

6. The method of claim 1, wherein the isolated peptide of SEQ. ID. No. 1 has an effective concentration of 5-100 μ

M in a pharmaceutical preparation.

7. The method of claim 1, wherein the pharmaceutical composition is administered subcutaneously, intramuscularly, intravenously, or intraperitoneally.

8. The method of claim 1, wherein the pharmaceutical composition comprises salts of chemical derivatives of SEQ ID NO.:

1.

9. The method of claim 1, wherein the subject is a mammal.

10. The method of claim 9, wherein the mammal is a human.